David Li, Co-Founder and CEO of Meliora Therapeutics, sits down with Neil to discuss why the mechanism of action for cancer therapies in development is poorly understood, how this leads to a high and costly clinical failure rate, and how Meliora's platform technology uncovers the true mechanism of action of a drug and it enables it to identify promising drug scaffolds to accelerate the development process.
Bioverge